Fcγ Receptor Function and the Design of Vaccination Strategies

Immunity

Volumn 47, Issue 2, 2017, Pages 224-233

  Bournazos, Stylianos ^a   Ravetch, Jeffrey V ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

antibodies; effector functions; immune regulation; immunity; immunization; therapy; vaccination

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN FC FRAGMENT; VACCINE;

HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGLOBULIN STRUCTURE; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE; VACCINATION; ANIMAL; IMMUNOLOGY; METABOLISM; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN ISOTYPES; IMMUNOMODULATION; RECEPTORS, IGG; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; VACCINATION; VACCINES;

EID: 85030458247     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2017.07.009     Document Type: Review

References (100)

1. Abès, R., Gélizé, E., Fridman, W.H., Teillaud, J.L., Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116 (2010), 926–934.
2. Albert, H., Collin, M., Dudziak, D., Ravetch, J.V., Nimmerjahn, F., In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc. Natl. Acad. Sci. USA 105 (2008), 15005–15009.
3. Amigorena, S., Salamero, J., Davoust, J., Fridman, W.H., Bonnerot, C., Tyrosine-containing motif that transduces cell activation signals also determines internalization and antigen presentation via type III receptors for IgG. Nature 358 (1992), 337–341.
4. Anthony, R.M., Wermeling, F., Karlsson, M.C., Ravetch, J.V., Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. USA 105 (2008), 19571–19578.
5. Anthony, R.M., Kobayashi, T., Wermeling, F., Ravetch, J.V., Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475 (2011), 110–113.
6. Anthony, R.M., Wermeling, F., Ravetch, J.V., Novel roles for the IgG Fc glycan. Ann. N Y Acad. Sci. 1253 (2012), 170–180.
7. Barouch, D.H., Whitney, J.B., Moldt, B., Klein, F., Oliveira, T.Y., Liu, J., Stephenson, K.E., Chang, H.W., Shekhar, K., Gupta, S., et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503 (2013), 224–228.
8. Bergtold, A., Desai, D.D., Gavhane, A., Clynes, R., Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. Immunity 23 (2005), 503–514.
9. Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., et al. Impact of FcgammaRIIa-FcgammaRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 27 (2009), 1122–1129.
10. Blank, M.C., Stefanescu, R.N., Masuda, E., Marti, F., King, P.D., Redecha, P.B., Wurzburger, R.J., Peterson, M.G., Tanaka, S., Pricop, L., Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum. Genet. 117 (2005), 220–227.
11. Bolland, S., Ravetch, J.V., Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 13 (2000), 277–285.
12. Bolland, S., Yim, Y.S., Tus, K., Wakeland, E.K., Ravetch, J.V., Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. J. Exp. Med. 195 (2002), 1167–1174.
13. Bonnerot, C., Briken, V., Brachet, V., Lankar, D., Cassard, S., Jabri, B., Amigorena, S., syk protein tyrosine kinase regulates Fc receptor gamma-chain-mediated transport to lysosomes. EMBO J. 17 (1998), 4606–4616.
14. Borthakur, S., Andrejeva, G., McDonnell, J.M., Basis of the intrinsic flexibility of the Cε3 domain of IgE. Biochemistry 50 (2011), 4608–4614.
15. Boruchov, A.M., Heller, G., Veri, M.C., Bonvini, E., Ravetch, J.V., Young, J.W., Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J. Clin. Invest. 115 (2005), 2914–2923.
16. Bouige, P., Iscaki, S., Pillot, J., Immune complexes as immunizing agents to increase the number of monoclonal antibody producing hybrids and to deviate the response to poorly immunogenic epitopes. Hybridoma 9 (1990), 519–526.
17. Bouige, P., Iscaki, S., Cosson, A., Pillot, J., Molecular analysis of the modulatory factors of the response to HBsAg in mice as an approach to HBV vaccine enhancement. FEMS Immunol. Med. Microbiol. 13 (1996), 71–79.
18. Bournazos, S., Ravetch, J.V., Fcγ receptor pathways during active and passive immunization. Immunol. Rev. 268 (2015), 88–103.
19. Bournazos, S., Woof, J.M., Hart, S.P., Dransfield, I., Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin. Exp. Immunol. 157 (2009), 244–254.
20. Bournazos, S., Chow, S.K., Abboud, N., Casadevall, A., Ravetch, J.V., Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. J. Clin. Invest. 124 (2014), 725–729.
21. Bournazos, S., Klein, F., Pietzsch, J., Seaman, M.S., Nussenzweig, M.C., Ravetch, J.V., Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158 (2014), 1243–1253.
22. Bournazos, S., DiLillo, D.J., Ravetch, J.V., The role of Fc-FcγR interactions in IgG-mediated microbial neutralization. J. Exp. Med. 212 (2015), 1361–1369.
23. Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., Watier, H., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002), 754–758.
24. Chan, M.A., Gigliotti, N.M., Matangkasombut, P., Gauld, S.B., Cambier, J.C., Rosenwasser, L.J., CD23-mediated cell signaling in human B cells differs from signaling in cells of the monocytic lineage. Clin. Immunol. 137 (2010), 330–336.
25. Clynes, R., Maizes, J.S., Guinamard, R., Ono, M., Takai, T., Ravetch, J.V., Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J. Exp. Med. 189 (1999), 179–185.
26. Clynes, R.A., Towers, T.L., Presta, L.G., Ravetch, J.V., Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6 (2000), 443–446.
27. Dale, D.C., Boxer, L., Liles, W.C., The phagocytes: neutrophils and monocytes. Blood 112 (2008), 935–945.
28. de Bono, J.S., Rha, S.Y., Stephenson, J., Schultes, B.C., Monroe, P., Eckhardt, G.S., Hammond, L.A., Whiteside, T.L., Nicodemus, C.F., Cermak, J.M., et al. Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann. Oncol. 15 (2004), 1825–1833.
29. de Man, Y.A., Dolhain, R.J., Hazes, J.M., Disease activity or remission of rheumatoid arthritis before, during and following pregnancy. Curr. Opin. Rheumatol. 26 (2014), 329–333.
30. Desai, D.D., Harbers, S.O., Flores, M., Colonna, L., Downie, M.P., Bergtold, A., Jung, S., Clynes, R., Fc gamma receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses. J. Immunol. 178 (2007), 6217–6226.
31. Dhaliwal, B., Yuan, D., Pang, M.O., Henry, A.J., Cain, K., Oxbrow, A., Fabiane, S.M., Beavil, A.J., McDonnell, J.M., Gould, H.J., Sutton, B.J., Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FcεRI. Proc. Natl. Acad. Sci. USA 109 (2012), 12686–12691.
32. Dhodapkar, K.M., Kaufman, J.L., Ehlers, M., Banerjee, D.K., Bonvini, E., Koenig, S., Steinman, R.M., Ravetch, J.V., Dhodapkar, M.V., Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl. Acad. Sci. USA 102 (2005), 2910–2915.
33. Dhodapkar, K.M., Banerjee, D., Connolly, J., Kukreja, A., Matayeva, E., Veri, M.C., Ravetch, J.V., Steinman, R.M., Dhodapkar, M.V., Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J. Exp. Med. 204 (2007), 1359–1369.
34. DiLillo, D.J., Ravetch, J.V., Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. Cell 161 (2015), 1035–1045.
35. Duchemin, A.M., Ernst, L.K., Anderson, C.L., Clustering of the high affinity Fc receptor for immunoglobulin G (Fc gamma RI) results in phosphorylation of its associated gamma-chain. J. Biol. Chem. 269 (1994), 12111–12117.
36. Espy, C., Morelle, W., Kavian, N., Grange, P., Goulvestre, C., Viallon, V., Chéreau, C., Pagnoux, C., Michalski, J.C., Guillevin, L., et al. Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener's). Arthritis Rheum. 63 (2011), 2105–2115.
37. Ferrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A.C., Stihle, M., et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. USA 108 (2011), 12669–12674.
38. Fiebiger, B.M., Maamary, J., Pincetic, A., Ravetch, J.V., Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proc. Natl. Acad. Sci. USA 112 (2015), E2385–E2394.
39. Floto, R.A., Clatworthy, M.R., Heilbronn, K.R., Rosner, D.R., MacAry, P.A., Rankin, A., Lehner, P.J., Ouwehand, W.H., Allen, J.M., Watkins, N.A., Smith, K.G., Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat. Med. 11 (2005), 1056–1058.
40. Foss, S., Watkinson, R., Sandlie, I., James, L.C., Andersen, J.T., TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity. Immunol. Rev. 268 (2015), 328–339.
41. Gerdes, C.A., Nicolini, V.G., Herter, S., van Puijenbroek, E., Lang, S., Roemmele, M., Moessner, E., Freytag, O., Friess, T., Ries, C.H., et al. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin. Cancer Res. 19 (2013), 1126–1138.
42. Ghetie, V., Ward, E.S., Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu. Rev. Immunol. 18 (2000), 739–766.
43. Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C.M., Chagorova, T., de la Serna, J., Dilhuydy, M.S., Illmer, T., et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370 (2014), 1101–1110.
44. Haddad, E.E., Whitfill, C.E., Avakian, A.P., Ricks, C.A., Andrews, P.D., Thoma, J.A., Wakenell, P.S., Efficacy of a novel infectious bursal disease virus immune complex vaccine in broiler chickens. Avian Dis. 41 (1997), 882–889.
45. Haigwood, N.L., Montefiori, D.C., Sutton, W.F., McClure, J., Watson, A.J., Voss, G., Hirsch, V.M., Richardson, B.A., Letvin, N.L., Hu, S.L., Johnson, P.R., Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. J. Virol. 78 (2004), 5983–5995.
46. Hilchey, S.P., Hyrien, O., Mosmann, T.R., Livingstone, A.M., Friedberg, J.W., Young, F., Fisher, R.I., Kelleher, R.J. Jr., Bankert, R.B., Bernstein, S.H., Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab. Blood 113 (2009), 3809–3812.
47. Hioe, C.E., Visciano, M.L., Kumar, R., Liu, J., Mack, E.A., Simon, R.E., Levy, D.N., Tuen, M., The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120. Vaccine 28 (2009), 352–360.
48. Hoffmann, E., Kotsias, F., Visentin, G., Bruhns, P., Savina, A., Amigorena, S., Autonomous phagosomal degradation and antigen presentation in dendritic cells. Proc. Natl. Acad. Sci. USA 109 (2012), 14556–14561.
49. Horton, H.M., Bernett, M.J., Pong, E., Peipp, M., Karki, S., Chu, S.Y., Richards, J.O., Vostiar, I., Joyce, P.F., Repp, R., et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 68 (2008), 8049–8057.
50. Jouvin, M.H., Adamczewski, M., Numerof, R., Letourneur, O., Vallé, A., Kinet, J.P., Differential control of the tyrosine kinases Lyn and Syk by the two signaling chains of the high affinity immunoglobulin E receptor. J. Biol. Chem. 269 (1994), 5918–5925.
51. Kaneko, Y., Nimmerjahn, F., Ravetch, J.V., Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006), 670–673.
52. Kiyoshi, M., Caaveiro, J.M., Kawai, T., Tashiro, S., Ide, T., Asaoka, Y., Hatayama, K., Tsumoto, K., Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI. Nat. Commun., 6, 2015, 6866.
53. Kumar, R., Tuen, M., Li, H., Tse, D.B., Hioe, C.E., Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation. Vaccine 29 (2011), 9064–9074.
54. Kumar, R., Tuen, M., Liu, J., Nàdas, A., Pan, R., Kong, X., Hioe, C.E., Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines. Vaccine 31 (2013), 5413–5421.
55. Kwak, L.W., Campbell, M.J., Czerwinski, D.K., Hart, S., Miller, R.A., Levy, R., Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327 (1992), 1209–1215.
56. Liu, S.D., Chalouni, C., Young, J.C., Junttila, T.T., Sliwkowski, M.X., Lowe, J.B., Afucosylated antibodies increase activation of FcγRIIIa-dependent signaling components to intensify processes promoting ADCC. Cancer Immunol. Res. 3 (2015), 173–183.
57. Lu, C.L., Murakowski, D.K., Bournazos, S., Schoofs, T., Sarkar, D., Halper-Stromberg, A., Horwitz, J.A., Nogueira, L., Golijanin, J., Gazumyan, A., et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352 (2016), 1001–1004.
58. Lund, J., Takahashi, N., Pound, J.D., Goodall, M., Jefferis, R., Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J. Immunol. 157 (1996), 4963–4969.
59. Mueller, M., Barros, P., Witherden, A.S., Roberts, A.L., Zhang, Z., Schaschl, H., Yu, C.Y., Hurles, M.E., Schaffner, C., Floto, R.A., et al. Genomic pathology of SLE-associated copy-number variation at the FCGR2C/FCGR3B/FCGR2B locus. Am. J. Hum. Genet. 92 (2013), 28–40.
60. Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26 (2008), 1789–1796.
61. Muta, T., Kurosaki, T., Misulovin, Z., Sanchez, M., Nussenzweig, M.C., Ravetch, J.V., A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signalling. Nature 368 (1994), 70–73.
62. Ng, C.T., Jaworski, J.P., Jayaraman, P., Sutton, W.F., Delio, P., Kuller, L., Anderson, D., Landucci, G., Richardson, B.A., Burton, D.R., et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat. Med. 16 (2010), 1117–1119.
63. Nimmerjahn, F., Ravetch, J.V., Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310 (2005), 1510–1512.
64. Odin, J.A., Edberg, J.C., Painter, C.J., Kimberly, R.P., Unkeless, J.C., Regulation of phagocytosis and [Ca2+]i flux by distinct regions of an Fc receptor. Science 254 (1991), 1785–1788.
65. Ohmi, Y., Ise, W., Harazono, A., Takakura, D., Fukuyama, H., Baba, Y., Narazaki, M., Shoda, H., Takahashi, N., Ohkawa, Y., et al. Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis. Nat. Commun., 7, 2016, 11205.
66. Ono, M., Bolland, S., Tempst, P., Ravetch, J.V., Role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor Fc(gamma)RIIB. Nature 383 (1996), 263–266.
67. Ono, M., Okada, H., Bolland, S., Yanagi, S., Kurosaki, T., Ravetch, J.V., Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling. Cell 90 (1997), 293–301.
68. Pearse, R.N., Kawabe, T., Bolland, S., Guinamard, R., Kurosaki, T., Ravetch, J.V., SHIP recruitment attenuates Fc gamma RIIB-induced B cell apoptosis. Immunity 10 (1999), 753–760.
69. Pincetic, A., Bournazos, S., DiLillo, D.J., Maamary, J., Wang, T.T., Dahan, R., Fiebiger, B.M., Ravetch, J.V., Type I and type II Fc receptors regulate innate and adaptive immunity. Nat. Immunol. 15 (2014), 707–716.
70. Pokrić, B., Sladić, D., Juros, S., Cajavec, S., Application of the immune complex for immune protection against viral disease. Vaccine 11 (1993), 655–659.
71. Regnault, A., Lankar, D., Lacabanne, V., Rodriguez, A., Théry, C., Rescigno, M., Saito, T., Verbeek, S., Bonnerot, C., Ricciardi-Castagnoli, P., Amigorena, S., Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189 (1999), 371–380.
72. Schoofs, T., Klein, F., Braunschweig, M., Kreider, E.F., Feldmann, A., Nogueira, L., Oliveira, T., Lorenzi, J.C., Parrish, E.H., Learn, G.H., et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352 (2016), 997–1001.
73. Shields, R.L., Namenuk, A.K., Hong, K., Meng, Y.G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276 (2001), 6591–6604.
74. Shields, R.L., Lai, J., Keck, R., O'Connell, L.Y., Hong, K., Meng, Y.G., Weikert, S.H., Presta, L.G., Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277 (2002), 26733–26740.
75. Smith, P., DiLillo, D.J., Bournazos, S., Li, F., Ravetch, J.V., Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc. Natl. Acad. Sci. USA 109 (2012), 6181–6186.
76. Soilleux, E.J., DC-SIGN (dendritic cell-specific ICAM-grabbing non-integrin) and DC-SIGN-related (DC-SIGNR): friend or foe?. Clin. Sci. 104 (2003), 437–446.
77. Sondermann, P., Huber, R., Oosthuizen, V., Jacob, U., The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406 (2000), 267–273.
78. Sondermann, P., Kaiser, J., Jacob, U., Molecular basis for immune complex recognition: a comparison of Fc-receptor structures. J. Mol. Biol. 309 (2001), 737–749.
79. Sondermann, P., Pincetic, A., Maamary, J., Lammens, K., Ravetch, J.V., General mechanism for modulating immunoglobulin effector function. Proc. Natl. Acad. Sci. USA 110 (2013), 9868–9872.
80. Su, K., Wu, J., Edberg, J.C., Li, X., Ferguson, P., Cooper, G.S., Langefeld, C.D., Kimberly, R.P., A promoter haplotype of the immunoreceptor tyrosine-based inhibitory motif-bearing FcgammaRIIb alters receptor expression and associates with autoimmunity. I. Regulatory FCGR2B polymorphisms and their association with systemic lupus erythematosus. J. Immunol. 172 (2004), 7186–7191.
81. Swanson, J.A., Hoppe, A.D., The coordination of signaling during Fc receptor-mediated phagocytosis. J. Leukoc. Biol. 76 (2004), 1093–1103.
82. Takai, T., Li, M., Sylvestre, D., Clynes, R., Ravetch, J.V., FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 76 (1994), 519–529.
83. Taylor, C., Hershman, D., Shah, N., Suciu-Foca, N., Petrylak, D.P., Taub, R., Vahdat, L., Cheng, B., Pegram, M., Knutson, K.L., Clynes, R., Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res. 13 (2007), 5133–5143.
84. te Velde, A.A., de Waal Malefijt, R., Huijbens, R.J., de Vries, J.E., Figdor, C.G., IL-10 stimulates monocyte Fc gamma R surface expression and cytotoxic activity. Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-gamma, IL-4, and IL-10. J. Immunol. 149 (1992), 4048–4052.
85. Theodoratou, E., Thaçi, K., Agakov, F., Timofeeva, M.N., Štambuk, J., Pučić-Baković, M., Vučković, F., Orchard, P., Agakova, A., Din, F.V., et al. Glycosylation of plasma IgG in colorectal cancer prognosis. Sci. Rep., 6, 2016, 28098.
86. Uciechowski, P., Schwarz, M., Gessner, J.E., Schmidt, R.E., Resch, K., Radeke, H.H., IFN-gamma induces the high-affinity Fc receptor I for IgG (CD64) on human glomerular mesangial cells. Eur. J. Immunol. 28 (1998), 2928–2935.
87. Unkeless, J.C., Shen, Z., Lin, C.W., DeBeus, E., Function of human Fc gamma RIIA and Fc gamma RIIIB. Semin. Immunol. 7 (1995), 37–44.
88. van de Geijn, F.E., Wuhrer, M., Selman, M.H., Willemsen, S.P., de Man, Y.A., Deelder, A.M., Hazes, J.M., Dolhain, R.J., Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res. Ther., 11, 2009, R193.
89. Visciano, M.L., Tuen, M., Chen, P.D., Hioe, C.E., Antibodies to the CD4-binding site of HIV-1 gp120 suppress gp120-specific CD4 T cell response while enhancing antibody response. Infect. Agent. Cancer, 3, 2008, 11.
90. von Behring, E., Wernicke, E., Ueber Immunisierung und Heilung von Versuchstieren bei der Diphterie. Z. Hyg. Infektionskr. 12 (1892), 10–44.
91. Wang, T.T., Maamary, J., Tan, G.S., Bournazos, S., Davis, C.W., Krammer, F., Schlesinger, S.J., Palese, P., Ahmed, R., Ravetch, J.V., Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy. Cell 162 (2015), 160–169.
92. Wang, T.T., Sewatanon, J., Memoli, M.J., Wrammert, J., Bournazos, S., Bhaumik, S.K., Pinsky, B.A., Chokephaibulkit, K., Onlamoon, N., Pattanapanyasat, K., et al. IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity. Science 355 (2017), 395–398.
93. Wen, Y.M., Mu, L., Shi, Y., Immunoregulatory functions of immune complexes in vaccine and therapy. EMBO Mol. Med. 8 (2016), 1120–1133.
94. Weng, W.K., Levy, R., Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21 (2003), 3940–3947.
95. Xiang, Z., Cutler, A.J., Brownlie, R.J., Fairfax, K., Lawlor, K.E., Severinson, E., Walker, E.U., Manz, R.A., Tarlinton, D.M., Smith, K.G., FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 8 (2007), 419–429.
96. Xu, D.Z., Huang, K.L., Zhao, K., Xu, L.F., Shi, N., Yuan, Z.H., Wen, Y.M., Vaccination with recombinant HBsAg-HBIG complex in healthy adults. Vaccine 23 (2005), 2658–2664.
97. Xu, D.Z., Wang, X.Y., Shen, X.L., Gong, G.Z., Ren, H., Guo, L.M., Sun, A.M., Xu, M., Li, L.J., Guo, X.H., et al., YIC Efficacy Trial Study Team. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J. Hepatol. 59 (2013), 450–456.
98. Yao, X., Zheng, B., Zhou, J., Xu, D.Z., Zhao, K., Sun, S.H., Yuan, Z.H., Wen, Y.M., Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 25 (2007), 1771–1779.
99. Yokota, A., Kikutani, H., Tanaka, T., Sato, R., Barsumian, E.L., Suemura, M., Kishimoto, T., Two species of human Fc epsilon receptor II (Fc epsilon RII/CD23): tissue-specific and IL-4-specific regulation of gene expression. Cell 55 (1988), 611–618.
100. Zhou, M.J., Brown, E.J., CR3 (Mac-1, alpha M beta 2, CD11b/CD18) and Fc gamma RIII cooperate in generation of a neutrophil respiratory burst: requirement for Fc gamma RIII and tyrosine phosphorylation. J. Cell Biol. 125 (1994), 1407–1416.